WESTLAKE VILLAGE, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced enrollment of the first patient in a Phase 2a clinical trial evaluating ARQ-252 as a potential treatment for vitiligo. ARQ-252 is a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1).
News Ticker
- [ September 26, 2023 ] Muscle Lab Ignites a Wellness Evolution with the Launch of GPT-4 Driven Custom Recovery Plans and Smart Lab Los Angeles Biotech News
- [ September 26, 2023 ] Herbalife Steps Up to Support Healthy Active Lifestyles for 10th Consecutive Year as Nutrition Partner for Downtown Los Angeles YMCA’s Stair Climb & Urban Hike Los Angeles Biotech News
- [ September 26, 2023 ] CLININICAL LAB SCIENTIST I – PD – IRVINE HEMATOLOGY – Hoag Memorial Hospital Presbyterian – Irvine, CA Los Angeles Biotech Jobs
- [ September 26, 2023 ] How TikTok’s algorithm and audiences are finally convincing Big Pharma to join Los Angeles Biotech News
- [ September 26, 2023 ] Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
